-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

Benzinga·07/13/2026 11:03:35
語音播報
JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.